Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study.
Qualls DA, Lambert N, Caimi PF, Merrill M, Pullarkat P, Godby RC, Bond DA, Wehmeyer GT, Romancik J, Amoozgar B, Leslie L, Nastoupil LJ, Crombie JL, Abramson JS, Khurana A, Nowakowski GS, Maddocks K, Rutherford SC, Kahl B, Okwali M, Buege MJ, Seshan V, Batlevi CL, Salles G. Qualls DA, et al. Blood. 2023 Dec 28;142(26):2327-2331. doi: 10.1182/blood.2023021274. Blood. 2023. PMID: 37738563
Optimizing CAR T cell therapy in lymphoma.
Qualls D, Salles G. Qualls D, et al. Hematol Oncol. 2021 Jun;39 Suppl 1:104-112. doi: 10.1002/hon.2844. Hematol Oncol. 2021. PMID: 34105817 Review.
A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma.
Qualls D, Lam HY, Whiting K, Kumar A, Matasar M, Owens C, Nichols C, Espeleta JA, Qiu A, Subzwari S, Biggar E, Seshan V, Salles G, Younes A, Batlevi C. Qualls D, et al. Blood Adv. 2022 Sep 27;6(18):5262-5266. doi: 10.1182/bloodadvances.2021006555. Blood Adv. 2022. PMID: 35171976 Free PMC article. Clinical Trial. No abstract available.
Retrospective characterization of nodal marginal zone lymphoma.
Stuver R, Drill E, Qualls D, Okwali M, Lee Batlevi C, Caron PC, Dogan A, Epstein-Peterson ZD, Falchi L, Hamlin PA, Horwitz SM, Imber BS, Intlekofer AM, Johnson WT, Khan N, Kumar A, Lahoud OB, Lue JK, Matasar MJ, Moskowitz AJ, Noy A, Owens CN, Palomba ML, Schöder H, Vardhana SA, Yahalom J, Zelenetz AD, Salles G, Straus DJ. Stuver R, et al. Blood Adv. 2023 Sep 12;7(17):4838-4847. doi: 10.1182/bloodadvances.2022009587. Blood Adv. 2023. PMID: 37307213 Free PMC article. Review.
Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study.
Qualls D, Noy A, Straus D, Matasar M, Moskowitz C, Seshan V, Dogan A, Salles G, Younes A, Zelenetz AD, Batlevi CL. Qualls D, et al. Leuk Lymphoma. 2023 Mar;64(3):738-741. doi: 10.1080/10428194.2022.2164194. Epub 2023 Jan 15. Leuk Lymphoma. 2023. PMID: 36642966 Free PMC article. Clinical Trial. No abstract available.
Long-term outcomes of patients with limited-stage ocular adnexal DLBCL treated with combined modality therapy in the rituximab era.
Qualls D, Imber BS, Okwali M, Hamlin PA, Kumar A, Lahoud OB, Matasar MJ, Noy A, Owens C, Zelenetz AD, North VS, Schöder H, Dogan A, Salles G, Yahalom J, Falchi L. Qualls D, et al. Br J Haematol. 2023 Feb;200(4):524-527. doi: 10.1111/bjh.18590. Epub 2022 Dec 9. Br J Haematol. 2023. PMID: 36484627 Free PMC article. No abstract available.
A road map for navigating CAR T hematotoxicity.
Qualls D, Jacobson C. Qualls D, et al. Blood. 2023 Sep 7;142(10):859-861. doi: 10.1182/blood.2023021305. Blood. 2023. PMID: 37676695 No abstract available.
Comorbidities in DLBCL: too "Severe4" CAR-T therapy?
Qualls D, Jacobson CA. Qualls D, et al. Blood Adv. 2023 Jul 25;7(14):3469-3471. doi: 10.1182/bloodadvances.2023009834. Blood Adv. 2023. PMID: 37450319 Free PMC article. No abstract available.
22 results